LOS ANGELES, CA / ACCESSWIRE / August 18, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired Ocular shares during the Class Period, should contact the firm before the September 5, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company's management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that these manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that, as a result of the above, the Company's public statements were materially false and misleading at all relevant times. When this information reached the public, shares of Ocular lowered in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was created by Brian Lundin, Esq., a securities litigator located in Los Angeles dedicated to upholding shareholders' rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/
SOURCE: Lundin Law PC